Demand for diabetic foot ulcer treatments grows
In June 2010, a company called Shire acquired Dermagraft (a synthetic skin) through its $750 million purchase of privately held Advanced BioHealing. The business deal was based on treating diabetic foot ulcers alone. Last year Dermagraft had U.S. sales of $146 million from treating slow-healing diabetic foot ulcers. People increasingly seek new foot ulcer treatments, as diagnoses for diabetes soar. Dermagraft's purpose is to promote healing of the ulcers to prevent infection, and the demand is increasing for products like that. It is estimated that for Americans over the age of 60, 30 percent will have diabetes and this will grow to more than 50 percent within a decade.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063